KCPG
EDIT icon

Kavar Capital Partners Group’s Editas Medicine EDIT Stock Holding History

Kavar Capital Partners Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,000
Closed -$25K – 225
2019
Q2 		$25K Buy
+1,000
New +$23.9K 0.01% 291
2018
Q3 		– Sell
-1,000
Closed -$36K – 183
2018
Q2 		$36K Hold
1,000
– – 0.02% 211
2018
Q1 		$33K Buy
+1,000
New +$35.6K 0.02% 220

Other funds holding EDIT

NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kavar Capital Partners Group's EDIT Position: Q3 2019 in Review

Kavar Capital Partners Group sold out of Editas Medicine (EDIT) in Q3 2019, closing a stake of 1,000 shares — an estimated $25K sold.

Kavar Capital Partners Group first reported a position in EDIT in Q1 2018 and held it in 3 quarters. The position peaked at $36K in Q2 2018. 187 funds tracked by Wall St. Rank hold EDIT as of Q3 2019.

  • Kavar Capital Partners Group reported no remaining Editas Medicine position as of Q3 2019 after selling out during the quarter.
  • Kavar Capital Partners Group sold 1,000 Editas Medicine shares in Q3 2019, an estimated $25K.
  • Kavar Capital Partners Group first reported a position in Editas Medicine in Q1 2018 and held it in 3 quarters.
  • Kavar Capital Partners Group's Editas Medicine position peaked at $36K in Q2 2018.
  • 187 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2019.

Based on Kavar Capital Partners Group's 13F filing for Q3 2019, filed 12 Nov 2019.